PriceTargets.com logo

CervoMed - CRVO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $21.86
  • Forecasted Upside: 141.25%
  • Number of Analysts: 11
  • Breakdown:
  • 3 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 1 Strong Buy Ratings
$9.06 As of 12/4/2025 05:00 PM ET
▲ +0.78 (9.42%)

This chart shows the closing price for CRVO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CervoMed Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRVO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRVO

Analyst Price Target is $21.86
▲ +141.25% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for CervoMed in the last 3 months. The average price target is $21.86, with a high forecast of $31.00 and a low forecast of $15.00. The average price target represents a 141.25% upside from the last price of $9.06.

This chart shows the closing price for CRVO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in CervoMed. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 3 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 3 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00
11/11/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00
11/5/2025HC WainwrightUpgradeNeutral ➝ Buy$11.00 ➝ $25.00
11/4/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$31.00
10/17/2025Roth CapitalSet TargetBuy ➝ Buy$20.00
10/13/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/8/2025HC WainwrightReiterated RatingNeutral ➝ Neutral$11.00
8/18/2025D. Boral CapitalBoost TargetBuy ➝ Buy$15.00 ➝ $31.00
8/12/2025Roth CapitalReiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
8/11/2025D. Boral CapitalBoost TargetBuy ➝ Buy$10.00 ➝ $15.00
8/11/2025Chardan CapitalReiterated RatingBuy ➝ Buy$15.00
7/29/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$21.00 ➝ $27.00
7/25/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00
6/11/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00
5/13/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/12/2025Chardan CapitalBoost TargetBuy ➝ Buy$14.00 ➝ $15.00
3/26/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/18/2025Roth MkmBoost TargetBuy ➝ Buy$15.00 ➝ $20.00
3/18/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$12.00 ➝ $21.00
3/17/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/13/2025Jones TradingUpgradeHold ➝ Buy$15.00
3/13/2025Chardan CapitalUpgradeNeutral ➝ Buy$14.00 ➝ $14.00
3/11/2025Brookline Capital ManagementUpgradeHold ➝ Strong-Buy
3/11/2025Roth MkmBoost TargetBuy ➝ Buy$7.00 ➝ $15.00
3/11/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
2/19/2025D. Boral CapitalUpgradeHold ➝ Buy$10.00
12/17/2024HC WainwrightDowngradeBuy ➝ Neutral
12/11/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$65.00 ➝ $12.00
12/11/2024Morgan StanleyReiterated RatingOverweight ➝ Underweight
12/11/2024Chardan CapitalReiterated RatingBuy ➝ Neutral
12/10/2024Brookline Capital ManagementDowngradeStrong-Buy ➝ Hold
12/10/2024D. Boral CapitalReiterated RatingBuy ➝ Hold
12/6/2024Roth MkmInitiated CoverageBuy$45.00
12/5/2024Roth CapitalUpgradeStrong-Buy
12/5/2024HC WainwrightInitiated CoverageBuy$42.00
11/27/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$34.00 ➝ $34.00
11/14/2024Chardan CapitalReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
9/18/2024Chardan CapitalInitiated CoverageBuy$55.00
7/26/2024Morgan StanleyInitiated CoverageOverweight$35.00
7/25/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$65.00 ➝ $65.00
7/8/2024Brookline Capital ManagementInitiated CoverageBuy$63.00
4/8/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$50.00 ➝ $65.00
2/15/2024Canaccord Genuity GroupInitiated CoverageBuy$50.00
2/15/2024Canaccord Genuity GroupInitiated CoverageBuy$50.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.07 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 8 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 6 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 23 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 23 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

CervoMed logo
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $9.06
Low: $8.15
High: $9.06

50 Day Range

MA: $8.00
Low: $6.74
High: $9.94

52 Week Range

Now: $9.06
Low: $1.80
High: $16.94

Volume

49,391 shs

Average Volume

83,272 shs

Market Capitalization

$83.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CervoMed?

The following sell-side analysts have issued research reports on CervoMed in the last year: Brookline Capital Management, Canaccord Genuity Group Inc., Chardan Capital, D. Boral Capital, HC Wainwright, Jones Trading, Morgan Stanley, Roth Capital, Roth Mkm, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for CRVO.

What is the current price target for CervoMed?

0 Wall Street analysts have set twelve-month price targets for CervoMed in the last year. Their average twelve-month price target is $21.86, suggesting a possible upside of 141.2%. D. Boral Capital has the highest price target set, predicting CRVO will reach $31.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $15.00 for CervoMed in the next year.
View the latest price targets for CRVO.

What is the current consensus analyst rating for CervoMed?

CervoMed currently has 3 sell ratings, 7 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CRVO.

What other companies compete with CervoMed?

Other companies that are similar to CervoMed include BioAge Labs, Kyverna Therapeutics, SOPHiA GENETICS, Amarin and Relmada Therapeutics. Learn More about companies similar to CervoMed.

How do I contact CervoMed's investor relations team?

CervoMed's physical mailing address is 2020 Avon Ct Ste 4, Charlottesville, Virginia 22902-8734. The company's listed phone number is 14342200718 and its investor relations email address is [email protected]. The official website for CervoMed is diffusionpharma.com. Learn More about contacing CervoMed investor relations.